3-isopropyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine | 1338247-53-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-isopropyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine
• 英文别名: 3-propan-2-yl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine
• CAS: 1338247-53-2
• 化学式: C₉H₁₅N₃
• 分子量: 165.24
• InChiKey: WHZFRXMNXMNTSG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  40.7
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
  申请人：BlinkBio, Inc.

  公开号：US20170202970A1

  公开（公告）日：2017-07-20

  Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

  本文描述了基于硅的共轭物，能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心，一个或多个可选的催化基团，一个定位基团，允许共轭物在靶细胞或组织内积累，一个或多个有效载荷基团（例如，治疗剂或成像剂），以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
• SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE
  申请人：PETRUKHIN Konstantin

  公开号：US20150315197A1

  公开（公告）日：2015-11-05

  The present invention provides a compound having the structure: wherein R 1 , R 2 , R 3 , R 4 , and R 5 are each independently H, halogen, CF 3 or C 1 -C 4 alkyl, wherein two or more of R 1 , R 2 , R 3 , R 4 , or R 5 are other than H; R 6 is H, OH, or halogen; and B is a substituted or unsubstituted heterobicycle, wherein when R 1 is CF 3 , R 2 is H, R 3 is F, R 4 is H, and R 5 is H, or R 1 is H, R 2 is CF 3 , R 3 is H, R 4 is CF 3 , and R 5 is H, or R 1 is Cl, R 2 is H, R 3 is H, R 4 is F, and R 5 is H, or R 1 is CF 3 , R 2 is H, R 3 is F, R 4 is H, and R 5 is H, or R 1 is CF 3 , R 2 is F, R 3 is H, R 4 is H, and R 5 is H, or R 1 is Cl, R 2 is F, R 3 is H, R 4 is H, and R 5 is H, then B is other than or a pharmaceutically acceptable salt thereof.

  本发明提供了一种具有以下结构的化合物：其中R1、R2、R3、R4和R5各自独立地为H、卤素、CF3或C1-C4烷基，其中R1、R2、R3、R4或R5中的两个或更多个不是H；R6为H、OH或卤素；B为取代或未取代的杂环，其中当R1为CF3、R2为H、R3为F、R4为H和R5为H，或者R1为H、R2为CF3、R3为H、R4为CF3和R5为H，或者R1为Cl、R2为H、R3为H、R4为F和R5为H，或者R1为CF3、R2为H、R3为F、R4为H和R5为H，或者R1为CF3、R2为F、R3为H、R4为H和R5为H，或者R1为Cl、R2为F、R3为H、R4为H和R5为H时，则B不是或其药学上可接受的盐。
• OCTAHYDROCYCLOPENTAPYRROLES, THEIR PREPARATION AND USE
  申请人：PETRUKHIN Konstantin

  公开号：US20160024007A1

  公开（公告）日：2016-01-28

  The present invention provides Octahydrocyclopentapyrrole compounds having the structure: (structurally represented) wherein psi is absent or present, and when present is a bond; R1, R2, R3, R4, and R5 are each independently H, halogen, CF, or C1-C4 alkyl; R6 is absent or present, and when present is H, OH, or halogen; A is absent or present, and when present is C(O) or C(O)NH; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is C(O); and when psi is present, then R6 is absent and when psi is absent, then R6 is present, or a pharmaceutically acceptable salt thereof, for treatment of diseases characterized by excessive lipofuscin accumulation in the retina.

  本发明提供了八氢环戊吡咯化合物，其结构如下：（结构式表示），其中psi不存在或存在，当存在时为键；R1、R2、R3、R4和R5各自独立地为H、卤素、CF或C1-C4烷基；R6不存在或存在，当存在时为H、OH或卤素；A不存在或存在，当存在时为C（O）或C（O）NH；B为取代或未取代的单环、双环、杂单环、杂双环、苄基、CO2H或（C1-C4烷基）-CO2H，其中当B为CO2H时，A存在且为C（O）；当psi存在时，R6不存在，当psi不存在时，R6存在，或其药学上可接受的盐，用于治疗以视网膜过多脂褐质沉积为特征的疾病。
• OCTAHYDROPYRROLOPYRROLES THEIR PREPARATION AND USE
  申请人：PETRUKHIN Konstantin

  公开号：US20160046632A1

  公开（公告）日：2016-02-18

  The present invention provides compounds comprising variously substituted octahydropyrrolopyrroles, their synthesis, methods of making, methods of using, compositions and formulations thereof.

  本发明提供了包含各种取代的八氢吡咯吡咯化合物，它们的合成方法，制备方法，使用方法，以及它们的组成和配方。
• N-ALKYL-2-PHENOXYETHANAMINES, THEIR PREPARATION AND USE
  申请人：PETRUKHIN Konstantin

  公开号：US20160046649A1

  公开（公告）日：2016-02-18

  The present invention provides a compound having the structure: (structurally represented) wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl; R6 is alkyl; A is absent or present, and when present is —C(O)— or —C(O)NH—; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is —C(O)—, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种具有以下结构的化合物：（结构表示）其中R1、R2、R3、R4和R5各自独立地为H、卤素、CF3或C1-C4烷基；R6为烷基；A不存在或存在，当存在时为—C（O）—或—C（O）NH—；B为取代或未取代的单环、双环、杂单环、杂双环、苄基、CO2H或（C1-C4烷基）-CO2H，其中当B为CO2H时，A存在且为—C（O）—，或其药学上可接受的盐。